TY  - JOUR
AU  - Vekić, Jelena
AU  - Stromsnes, Kristine
AU  - Mazzalai, Stefania
AU  - Zeljković, Aleksandra
AU  - Rizzo, Manfredi
AU  - Gambini, Juan
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5340
AB  - Oxidative stress is the consequence of an overproduction of reactive oxygen species (ROS) that exceeds the antioxidant defense mechanisms. Increased levels of ROS contribute to the development of cardiovascular disorders through oxidative damage to macromolecules, particularly by oxidation of plasma lipoproteins. One of the most prominent features of atherogenic dyslipidemia is plasma accumulation of small dense LDL (sdLDL) particles, characterized by an increased susceptibility to oxidation. Indeed, a considerable and diverse body of evidence from animal models and epidemiological studies was generated supporting oxidative modification of sdLDL particles as the earliest event in atherogenesis. Lipid peroxidation of LDL particles results in the formation of various bioactive species that contribute to the atherosclerotic process through different pathophysiological mechanisms, including foam cell formation, direct detrimental effects, and receptor-mediated activation of pro-inflammatory signaling pathways. In this paper, we will discuss recent data on the pathophysiological role of oxidative stress and atherogenic dyslipidemia and their interplay in the development of atherosclerosis. In addition, a special focus will be placed on the clinical applicability of novel, promising biomarkers of these processes.
PB  - MDPI
T2  - Biomedicines
T1  - Oxidative Stress, Atherogenic Dyslipidemia, and Cardiovascular Risk
VL  - 11
IS  - 11
DO  - 10.3390/biomedicines11112897
ER  - 

@article{
author = "Vekić, Jelena and Stromsnes, Kristine and Mazzalai, Stefania and Zeljković, Aleksandra and Rizzo, Manfredi and Gambini, Juan",
year = "2023",
abstract = "Oxidative stress is the consequence of an overproduction of reactive oxygen species (ROS) that exceeds the antioxidant defense mechanisms. Increased levels of ROS contribute to the development of cardiovascular disorders through oxidative damage to macromolecules, particularly by oxidation of plasma lipoproteins. One of the most prominent features of atherogenic dyslipidemia is plasma accumulation of small dense LDL (sdLDL) particles, characterized by an increased susceptibility to oxidation. Indeed, a considerable and diverse body of evidence from animal models and epidemiological studies was generated supporting oxidative modification of sdLDL particles as the earliest event in atherogenesis. Lipid peroxidation of LDL particles results in the formation of various bioactive species that contribute to the atherosclerotic process through different pathophysiological mechanisms, including foam cell formation, direct detrimental effects, and receptor-mediated activation of pro-inflammatory signaling pathways. In this paper, we will discuss recent data on the pathophysiological role of oxidative stress and atherogenic dyslipidemia and their interplay in the development of atherosclerosis. In addition, a special focus will be placed on the clinical applicability of novel, promising biomarkers of these processes.",
publisher = "MDPI",
journal = "Biomedicines",
title = "Oxidative Stress, Atherogenic Dyslipidemia, and Cardiovascular Risk",
volume = "11",
number = "11",
doi = "10.3390/biomedicines11112897"
}

Vekić, J., Stromsnes, K., Mazzalai, S., Zeljković, A., Rizzo, M.,& Gambini, J.. (2023). Oxidative Stress, Atherogenic Dyslipidemia, and Cardiovascular Risk. in Biomedicines
MDPI., 11(11).
https://doi.org/10.3390/biomedicines11112897

Vekić J, Stromsnes K, Mazzalai S, Zeljković A, Rizzo M, Gambini J. Oxidative Stress, Atherogenic Dyslipidemia, and Cardiovascular Risk. in Biomedicines. 2023;11(11).
doi:10.3390/biomedicines11112897 .

Vekić, Jelena, Stromsnes, Kristine, Mazzalai, Stefania, Zeljković, Aleksandra, Rizzo, Manfredi, Gambini, Juan, "Oxidative Stress, Atherogenic Dyslipidemia, and Cardiovascular Risk" in Biomedicines, 11, no. 11 (2023),
https://doi.org/10.3390/biomedicines11112897 . .

TY  - JOUR
AU  - Vekić, Jelena
AU  - Pantea Stoian, Anca
AU  - Rizzo, Manfredi
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4429
PB  - Elsevier Inc.
T2  - Journal of Diabetes and its Complications
T1  - Lipoprotein subclasses and early kidney dysfunction in young type 1 diabetes mellitus patients
VL  - 37
IS  - 3
DO  - 10.1016/j.jdiacomp.2023.108412
ER  - 

@article{
author = "Vekić, Jelena and Pantea Stoian, Anca and Rizzo, Manfredi",
year = "2023",
publisher = "Elsevier Inc.",
journal = "Journal of Diabetes and its Complications",
title = "Lipoprotein subclasses and early kidney dysfunction in young type 1 diabetes mellitus patients",
volume = "37",
number = "3",
doi = "10.1016/j.jdiacomp.2023.108412"
}

Vekić, J., Pantea Stoian, A.,& Rizzo, M.. (2023). Lipoprotein subclasses and early kidney dysfunction in young type 1 diabetes mellitus patients. in Journal of Diabetes and its Complications
Elsevier Inc.., 37(3).
https://doi.org/10.1016/j.jdiacomp.2023.108412

Vekić J, Pantea Stoian A, Rizzo M. Lipoprotein subclasses and early kidney dysfunction in young type 1 diabetes mellitus patients. in Journal of Diabetes and its Complications. 2023;37(3).
doi:10.1016/j.jdiacomp.2023.108412 .

Vekić, Jelena, Pantea Stoian, Anca, Rizzo, Manfredi, "Lipoprotein subclasses and early kidney dysfunction in young type 1 diabetes mellitus patients" in Journal of Diabetes and its Complications, 37, no. 3 (2023),
https://doi.org/10.1016/j.jdiacomp.2023.108412 . .

TY  - JOUR
AU  - Vekić, Jelena
AU  - Vujčić, Sanja
AU  - Bufan, Biljana
AU  - Bojanin, Dragana
AU  - Al-Hashmi, Khamis
AU  - Al-Rasadi, Khaild
AU  - Stoian, Anca Pantea
AU  - Zeljković, Aleksandra
AU  - Rizzo, Manfredi
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4415
AB  - Disorders of lipoprotein metabolism and glucose homeostasis are common consequences of insulin resistance and usually co-segregate in patients with metabolic syndrome and type 2 diabetes mellitus (DM). Insulin-resistant subjects are characterized by atherogenic dyslipidemia, a specific lipid pattern which includes hypertriglyceridemia, reduced high-density lipoprotein cholesterol level, and increased proportion of small, dense low-density lipoprotein (LDL). Chronic hyperglycemia favors the processes of non-enzymatic glycation, leading to the increased production of advanced glycation end products (AGEs). Apart from direct harmful effects, AGEs are also potent inducers of oxidative stress and inflammation. In addition, increased AGEs’ production may induce further qualitative modifications of small, dense LDL particles, converting them to glycated LDLs. These particles are even more atherogenic and may confer an increased cardiovascular risk. In this narrative review, we summarize the available evidence of the pathophysiological role and clinical importance of circulating AGEs and glycated LDLs in patients with dyslipidemia, particularly those with DM and related complications. In addition, we discuss recent advances and the issues that should be improved regarding laboratory assessment of AGEs and glycated LDLs, as well as the possibilities for their therapeutic modulation.
PB  - MDPI
T2  - Metabolites
T1  - The Role of Advanced Glycation End Products on Dyslipidemia
VL  - 13
IS  - 1
DO  - 10.3390/metabo13010077
ER  - 

@article{
author = "Vekić, Jelena and Vujčić, Sanja and Bufan, Biljana and Bojanin, Dragana and Al-Hashmi, Khamis and Al-Rasadi, Khaild and Stoian, Anca Pantea and Zeljković, Aleksandra and Rizzo, Manfredi",
year = "2023",
abstract = "Disorders of lipoprotein metabolism and glucose homeostasis are common consequences of insulin resistance and usually co-segregate in patients with metabolic syndrome and type 2 diabetes mellitus (DM). Insulin-resistant subjects are characterized by atherogenic dyslipidemia, a specific lipid pattern which includes hypertriglyceridemia, reduced high-density lipoprotein cholesterol level, and increased proportion of small, dense low-density lipoprotein (LDL). Chronic hyperglycemia favors the processes of non-enzymatic glycation, leading to the increased production of advanced glycation end products (AGEs). Apart from direct harmful effects, AGEs are also potent inducers of oxidative stress and inflammation. In addition, increased AGEs’ production may induce further qualitative modifications of small, dense LDL particles, converting them to glycated LDLs. These particles are even more atherogenic and may confer an increased cardiovascular risk. In this narrative review, we summarize the available evidence of the pathophysiological role and clinical importance of circulating AGEs and glycated LDLs in patients with dyslipidemia, particularly those with DM and related complications. In addition, we discuss recent advances and the issues that should be improved regarding laboratory assessment of AGEs and glycated LDLs, as well as the possibilities for their therapeutic modulation.",
publisher = "MDPI",
journal = "Metabolites",
title = "The Role of Advanced Glycation End Products on Dyslipidemia",
volume = "13",
number = "1",
doi = "10.3390/metabo13010077"
}

Vekić, J., Vujčić, S., Bufan, B., Bojanin, D., Al-Hashmi, K., Al-Rasadi, K., Stoian, A. P., Zeljković, A.,& Rizzo, M.. (2023). The Role of Advanced Glycation End Products on Dyslipidemia. in Metabolites
MDPI., 13(1).
https://doi.org/10.3390/metabo13010077

Vekić J, Vujčić S, Bufan B, Bojanin D, Al-Hashmi K, Al-Rasadi K, Stoian AP, Zeljković A, Rizzo M. The Role of Advanced Glycation End Products on Dyslipidemia. in Metabolites. 2023;13(1).
doi:10.3390/metabo13010077 .

Vekić, Jelena, Vujčić, Sanja, Bufan, Biljana, Bojanin, Dragana, Al-Hashmi, Khamis, Al-Rasadi, Khaild, Stoian, Anca Pantea, Zeljković, Aleksandra, Rizzo, Manfredi, "The Role of Advanced Glycation End Products on Dyslipidemia" in Metabolites, 13, no. 1 (2023),
https://doi.org/10.3390/metabo13010077 . .

TY  - JOUR
AU  - Lalosević, Miodrag
AU  - Kotur-Stevuljević, Jelena
AU  - Vekić, Jelena
AU  - Rizzo, Manfredi
AU  - Kosanović, Tijana
AU  - Blagojević-Perović, Ivana
AU  - Zeljković, Aleksandra
AU  - Jeremić, Danilo
AU  - Mihajlović, Marija
AU  - Petković, Aleksa
AU  - Hajdarpasić, Lejla
AU  - Đorđević, Marjana
AU  - Dobrilović, Violeta
AU  - Erceg, Sanja
AU  - Vujčić, Sanja
AU  - Marjanović, Jelena
AU  - Jovanović-Milijić, Jovana
AU  - Saponjski, Jovica
AU  - Bogavac-Stanojević, Nataša
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4335
AB  - Background. Metabolic alterations, particularly disorders of lipoprotein metabolism in COVID-19, may affect the course and outcome of the disease. This study aims at evaluating the lipoprotein profile and redox status in SARS-CoV-2 infected patients with different pneumonia severity and their association with lethal outcomes. Methods. The prospective cohort study was performed on 98 COVID-19 patients with mild, moderate, and severe pneumonia. Lipid and inflammatory parameters, lipoprotein subclasses, and redox status biomarkers were determined at the study entry and after one week. Results. Compared to patients with mild and moderate pneumonia, severely ill patients had higher oxidised low-density lipoprotein (oxLDL) and malondialdehyde levels and lower high-density lipoprotein cholesterol (HDL-C) concentrations and paraoxonase 1 activity. Reduction in the proportion of large HDL 2a subclasses with a concomitant increase in the proportion of smallest HDL 3c and small dense LDL (sdLDL) particles was observed in patients with severe disease during the time. However, these changes were reversed in the mild and moderate groups. The results showed a positive association between changes in oxLDL and total antioxidative status. However, prooxidants and antioxidants in plasma were lower in patients with lethal outcomes. Conclusions. Increased levels of oxLDL and sdLDL particles may contribute to the severity of COVID-19. The role of oxidative stress should be clarified in further studies, mainly its association with lethal outcomes.
PB  - Hindawi Limited
T2  - Oxidative Medicine and Cellular Longevity
T1  - Alteration in Redox Status and Lipoprotein Profile in COVID-19 Patients with Mild, Moderate, and Severe Pneumonia
VL  - 2022
DO  - 10.1155/2022/8067857
ER  - 

@article{
author = "Lalosević, Miodrag and Kotur-Stevuljević, Jelena and Vekić, Jelena and Rizzo, Manfredi and Kosanović, Tijana and Blagojević-Perović, Ivana and Zeljković, Aleksandra and Jeremić, Danilo and Mihajlović, Marija and Petković, Aleksa and Hajdarpasić, Lejla and Đorđević, Marjana and Dobrilović, Violeta and Erceg, Sanja and Vujčić, Sanja and Marjanović, Jelena and Jovanović-Milijić, Jovana and Saponjski, Jovica and Bogavac-Stanojević, Nataša",
year = "2022",
abstract = "Background. Metabolic alterations, particularly disorders of lipoprotein metabolism in COVID-19, may affect the course and outcome of the disease. This study aims at evaluating the lipoprotein profile and redox status in SARS-CoV-2 infected patients with different pneumonia severity and their association with lethal outcomes. Methods. The prospective cohort study was performed on 98 COVID-19 patients with mild, moderate, and severe pneumonia. Lipid and inflammatory parameters, lipoprotein subclasses, and redox status biomarkers were determined at the study entry and after one week. Results. Compared to patients with mild and moderate pneumonia, severely ill patients had higher oxidised low-density lipoprotein (oxLDL) and malondialdehyde levels and lower high-density lipoprotein cholesterol (HDL-C) concentrations and paraoxonase 1 activity. Reduction in the proportion of large HDL 2a subclasses with a concomitant increase in the proportion of smallest HDL 3c and small dense LDL (sdLDL) particles was observed in patients with severe disease during the time. However, these changes were reversed in the mild and moderate groups. The results showed a positive association between changes in oxLDL and total antioxidative status. However, prooxidants and antioxidants in plasma were lower in patients with lethal outcomes. Conclusions. Increased levels of oxLDL and sdLDL particles may contribute to the severity of COVID-19. The role of oxidative stress should be clarified in further studies, mainly its association with lethal outcomes.",
publisher = "Hindawi Limited",
journal = "Oxidative Medicine and Cellular Longevity",
title = "Alteration in Redox Status and Lipoprotein Profile in COVID-19 Patients with Mild, Moderate, and Severe Pneumonia",
volume = "2022",
doi = "10.1155/2022/8067857"
}

Lalosević, M., Kotur-Stevuljević, J., Vekić, J., Rizzo, M., Kosanović, T., Blagojević-Perović, I., Zeljković, A., Jeremić, D., Mihajlović, M., Petković, A., Hajdarpasić, L., Đorđević, M., Dobrilović, V., Erceg, S., Vujčić, S., Marjanović, J., Jovanović-Milijić, J., Saponjski, J.,& Bogavac-Stanojević, N.. (2022). Alteration in Redox Status and Lipoprotein Profile in COVID-19 Patients with Mild, Moderate, and Severe Pneumonia. in Oxidative Medicine and Cellular Longevity
Hindawi Limited., 2022.
https://doi.org/10.1155/2022/8067857

Lalosević M, Kotur-Stevuljević J, Vekić J, Rizzo M, Kosanović T, Blagojević-Perović I, Zeljković A, Jeremić D, Mihajlović M, Petković A, Hajdarpasić L, Đorđević M, Dobrilović V, Erceg S, Vujčić S, Marjanović J, Jovanović-Milijić J, Saponjski J, Bogavac-Stanojević N. Alteration in Redox Status and Lipoprotein Profile in COVID-19 Patients with Mild, Moderate, and Severe Pneumonia. in Oxidative Medicine and Cellular Longevity. 2022;2022.
doi:10.1155/2022/8067857 .

Lalosević, Miodrag, Kotur-Stevuljević, Jelena, Vekić, Jelena, Rizzo, Manfredi, Kosanović, Tijana, Blagojević-Perović, Ivana, Zeljković, Aleksandra, Jeremić, Danilo, Mihajlović, Marija, Petković, Aleksa, Hajdarpasić, Lejla, Đorđević, Marjana, Dobrilović, Violeta, Erceg, Sanja, Vujčić, Sanja, Marjanović, Jelena, Jovanović-Milijić, Jovana, Saponjski, Jovica, Bogavac-Stanojević, Nataša, "Alteration in Redox Status and Lipoprotein Profile in COVID-19 Patients with Mild, Moderate, and Severe Pneumonia" in Oxidative Medicine and Cellular Longevity, 2022 (2022),
https://doi.org/10.1155/2022/8067857 . .

TY  - JOUR
AU  - Vujčić, Sanja
AU  - Kotur-Stevuljević, Jelena
AU  - Vekić, Jelena
AU  - Perović-Blagojević, Iva
AU  - Stefanović, Tatjana
AU  - Ilić-Mijailović, Sanja
AU  - Koprivica Uzelac, Branka
AU  - Bosić, Srećko
AU  - Antonić, Tamara
AU  - Guzonjić, Azra
AU  - Mastilović, Ana-Marija
AU  - Marković, Zorica
AU  - Rizzo, Manfredi
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4369
AB  - Background and Objectives: Diabetic foot (DF) development is driven by complex interactions of hyperglycemia, inflammation, and oxidative stress (OS). We aimed to investigate OS and inflammatory biomarkers in patients with DF and their potential to improve early diagnosis and management of DF. Materials and Methods: The prooxidant–antioxidant balance (PAB), superoxide dismutase (SOD), total oxidative status (TOS), total sulfhydryl groups (SHG), routine biochemical parameters, and complete blood count were determined in 42 patients with type-2 DM, of which 23 patients had DF, while 19 patients were without DF complications. The neutrophils-to-lymphocyte ratio (NLR) was evaluated as a biomarker of inflammation. Results: Patients with DF had significantly higher (p < 0.05) PAB levels (170 ± 33.9 U/L) compared to those without DF complications (142 ± 31.3 U/L). In addition, patients with DF had significantly reduced SOD activities (p < 0.01). NLR values were significantly higher in the DF group (median: 2.8; interquartile range: 2.0–4.3) than in the group without DF (median: 1.4; interquartile range: 1.4–2.1; p < 0.01). A positive correlation was found between the PAB and NLR index (r = 0.449; p < 0.05). The diagnostic accuracy of both PAB (AUC = 0.741; p < 0.01) and NLR (AUC = 0.760; p < 0.01) was estimated as acceptable. Conclusions: In conclusion, the development of DF is associated with enhanced OS and inflammation processes. PAB and NLR could be useful non-invasive biomarkers of DF development.
PB  - MDPI
T2  - Medicina (Lithuania)
T1  - Oxidative Stress and Inflammatory Biomarkers in Patients with Diabetic Foot
VL  - 58
IS  - 12
DO  - 10.3390/medicina58121866
ER  - 

@article{
author = "Vujčić, Sanja and Kotur-Stevuljević, Jelena and Vekić, Jelena and Perović-Blagojević, Iva and Stefanović, Tatjana and Ilić-Mijailović, Sanja and Koprivica Uzelac, Branka and Bosić, Srećko and Antonić, Tamara and Guzonjić, Azra and Mastilović, Ana-Marija and Marković, Zorica and Rizzo, Manfredi",
year = "2022",
abstract = "Background and Objectives: Diabetic foot (DF) development is driven by complex interactions of hyperglycemia, inflammation, and oxidative stress (OS). We aimed to investigate OS and inflammatory biomarkers in patients with DF and their potential to improve early diagnosis and management of DF. Materials and Methods: The prooxidant–antioxidant balance (PAB), superoxide dismutase (SOD), total oxidative status (TOS), total sulfhydryl groups (SHG), routine biochemical parameters, and complete blood count were determined in 42 patients with type-2 DM, of which 23 patients had DF, while 19 patients were without DF complications. The neutrophils-to-lymphocyte ratio (NLR) was evaluated as a biomarker of inflammation. Results: Patients with DF had significantly higher (p < 0.05) PAB levels (170 ± 33.9 U/L) compared to those without DF complications (142 ± 31.3 U/L). In addition, patients with DF had significantly reduced SOD activities (p < 0.01). NLR values were significantly higher in the DF group (median: 2.8; interquartile range: 2.0–4.3) than in the group without DF (median: 1.4; interquartile range: 1.4–2.1; p < 0.01). A positive correlation was found between the PAB and NLR index (r = 0.449; p < 0.05). The diagnostic accuracy of both PAB (AUC = 0.741; p < 0.01) and NLR (AUC = 0.760; p < 0.01) was estimated as acceptable. Conclusions: In conclusion, the development of DF is associated with enhanced OS and inflammation processes. PAB and NLR could be useful non-invasive biomarkers of DF development.",
publisher = "MDPI",
journal = "Medicina (Lithuania)",
title = "Oxidative Stress and Inflammatory Biomarkers in Patients with Diabetic Foot",
volume = "58",
number = "12",
doi = "10.3390/medicina58121866"
}

Vujčić, S., Kotur-Stevuljević, J., Vekić, J., Perović-Blagojević, I., Stefanović, T., Ilić-Mijailović, S., Koprivica Uzelac, B., Bosić, S., Antonić, T., Guzonjić, A., Mastilović, A., Marković, Z.,& Rizzo, M.. (2022). Oxidative Stress and Inflammatory Biomarkers in Patients with Diabetic Foot. in Medicina (Lithuania)
MDPI., 58(12).
https://doi.org/10.3390/medicina58121866

Vujčić S, Kotur-Stevuljević J, Vekić J, Perović-Blagojević I, Stefanović T, Ilić-Mijailović S, Koprivica Uzelac B, Bosić S, Antonić T, Guzonjić A, Mastilović A, Marković Z, Rizzo M. Oxidative Stress and Inflammatory Biomarkers in Patients with Diabetic Foot. in Medicina (Lithuania). 2022;58(12).
doi:10.3390/medicina58121866 .

Vujčić, Sanja, Kotur-Stevuljević, Jelena, Vekić, Jelena, Perović-Blagojević, Iva, Stefanović, Tatjana, Ilić-Mijailović, Sanja, Koprivica Uzelac, Branka, Bosić, Srećko, Antonić, Tamara, Guzonjić, Azra, Mastilović, Ana-Marija, Marković, Zorica, Rizzo, Manfredi, "Oxidative Stress and Inflammatory Biomarkers in Patients with Diabetic Foot" in Medicina (Lithuania), 58, no. 12 (2022),
https://doi.org/10.3390/medicina58121866 . .

TY  - JOUR
AU  - Zeljković, Aleksandra
AU  - Ardalić, Daniela
AU  - Vekić, Jelena
AU  - Antonić, Tamara
AU  - Vladimirov, Sandra
AU  - Rizzo, Manfredi
AU  - Gojković, Tamara
AU  - Ivanišević, Jasmina
AU  - Mihajlović, Marija
AU  - Vujčić, Sanja
AU  - Cabunac, Petar
AU  - Spasojević-Kalimanovska, Vesna
AU  - Miković, Željko
AU  - Stefanović, Aleksandra
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4314
AB  - Metabolic disorders in pregnancy, particularly gestational diabetes mellitus (GDM), are associated with an increased risk for adverse pregnancy outcome and long-term cardiometabolic health of mother and child. This study analyzed changes of serum cholesterol synthesis and absorption markers during the course of high-risk pregnancies, with respect to the development of GDM. Possible associations of maternal lipid biomarkers with neonatal characteristics were also investigated. The study included 63 women with high risk for development of pregnancy complications. Size and proportions of small low-density (LDL) and high-density lipoprotein (HDL) particles were assessed across trimesters (T1–T3), as well as concentrations of cholesterol synthesis (lathosterol, desmosterol) and absorption markers (campesterol, β-sitosterol). During the study, 15 women developed GDM, while 48 had no complications (non-GDM). As compared to the non-GDM group, women with GDM had significantly higher triglycerides in each trimester, while having a lower HDL-C level in T3. In addition, they had significantly lower levels of β-sitosterol in T3 (p < 0.05). Cholesterol synthesis markers increased across trimesters in both groups. A decrease in serum β-sitosterol levels during the course of pregnancies affected by GDM was observed. The prevalence of small-sized HDL decreased in non-GDM, while in the GDM group remained unchanged across trimesters. Newborn’s size in the non-GDM group was significantly higher (p < 0.01) and inversely associated with proportions of both small, dense LDL and HDL particles (p < 0.05) in maternal plasma in T1. In conclusion, high-risk pregnancies affected by GDM are characterized by altered cholesterol absorption and HDL maturation. Advanced lipid testing may indicate disturbed lipid homeostasis in GDM.
PB  - MDPI
T2  - Metabolites
T1  - Effects of Gestational Diabetes Mellitus on Cholesterol Metabolism in Women with High-Risk Pregnancies: Possible Implications for Neonatal Outcome
VL  - 12
IS  - 10
DO  - 10.3390/metabo12100959
ER  - 

@article{
author = "Zeljković, Aleksandra and Ardalić, Daniela and Vekić, Jelena and Antonić, Tamara and Vladimirov, Sandra and Rizzo, Manfredi and Gojković, Tamara and Ivanišević, Jasmina and Mihajlović, Marija and Vujčić, Sanja and Cabunac, Petar and Spasojević-Kalimanovska, Vesna and Miković, Željko and Stefanović, Aleksandra",
year = "2022",
abstract = "Metabolic disorders in pregnancy, particularly gestational diabetes mellitus (GDM), are associated with an increased risk for adverse pregnancy outcome and long-term cardiometabolic health of mother and child. This study analyzed changes of serum cholesterol synthesis and absorption markers during the course of high-risk pregnancies, with respect to the development of GDM. Possible associations of maternal lipid biomarkers with neonatal characteristics were also investigated. The study included 63 women with high risk for development of pregnancy complications. Size and proportions of small low-density (LDL) and high-density lipoprotein (HDL) particles were assessed across trimesters (T1–T3), as well as concentrations of cholesterol synthesis (lathosterol, desmosterol) and absorption markers (campesterol, β-sitosterol). During the study, 15 women developed GDM, while 48 had no complications (non-GDM). As compared to the non-GDM group, women with GDM had significantly higher triglycerides in each trimester, while having a lower HDL-C level in T3. In addition, they had significantly lower levels of β-sitosterol in T3 (p < 0.05). Cholesterol synthesis markers increased across trimesters in both groups. A decrease in serum β-sitosterol levels during the course of pregnancies affected by GDM was observed. The prevalence of small-sized HDL decreased in non-GDM, while in the GDM group remained unchanged across trimesters. Newborn’s size in the non-GDM group was significantly higher (p < 0.01) and inversely associated with proportions of both small, dense LDL and HDL particles (p < 0.05) in maternal plasma in T1. In conclusion, high-risk pregnancies affected by GDM are characterized by altered cholesterol absorption and HDL maturation. Advanced lipid testing may indicate disturbed lipid homeostasis in GDM.",
publisher = "MDPI",
journal = "Metabolites",
title = "Effects of Gestational Diabetes Mellitus on Cholesterol Metabolism in Women with High-Risk Pregnancies: Possible Implications for Neonatal Outcome",
volume = "12",
number = "10",
doi = "10.3390/metabo12100959"
}

Zeljković, A., Ardalić, D., Vekić, J., Antonić, T., Vladimirov, S., Rizzo, M., Gojković, T., Ivanišević, J., Mihajlović, M., Vujčić, S., Cabunac, P., Spasojević-Kalimanovska, V., Miković, Ž.,& Stefanović, A.. (2022). Effects of Gestational Diabetes Mellitus on Cholesterol Metabolism in Women with High-Risk Pregnancies: Possible Implications for Neonatal Outcome. in Metabolites
MDPI., 12(10).
https://doi.org/10.3390/metabo12100959

Zeljković A, Ardalić D, Vekić J, Antonić T, Vladimirov S, Rizzo M, Gojković T, Ivanišević J, Mihajlović M, Vujčić S, Cabunac P, Spasojević-Kalimanovska V, Miković Ž, Stefanović A. Effects of Gestational Diabetes Mellitus on Cholesterol Metabolism in Women with High-Risk Pregnancies: Possible Implications for Neonatal Outcome. in Metabolites. 2022;12(10).
doi:10.3390/metabo12100959 .

Zeljković, Aleksandra, Ardalić, Daniela, Vekić, Jelena, Antonić, Tamara, Vladimirov, Sandra, Rizzo, Manfredi, Gojković, Tamara, Ivanišević, Jasmina, Mihajlović, Marija, Vujčić, Sanja, Cabunac, Petar, Spasojević-Kalimanovska, Vesna, Miković, Željko, Stefanović, Aleksandra, "Effects of Gestational Diabetes Mellitus on Cholesterol Metabolism in Women with High-Risk Pregnancies: Possible Implications for Neonatal Outcome" in Metabolites, 12, no. 10 (2022),
https://doi.org/10.3390/metabo12100959 . .

TY  - JOUR
AU  - Vekić, Jelena
AU  - Zeljković, Aleksandra
AU  - Stefanović, Aleksandra
AU  - Bogavac-Stanojević, Nataša
AU  - Ilias, Ioannis
AU  - Silva-Nunes, José
AU  - Pantea Stoian, Anca
AU  - Janez, Andrej
AU  - Rizzo, Manfredi
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4100
AB  - Compelling evidence supports the causative link between increased levels of low-density lipoprotein cholesterol (LDL-C) and atherosclerotic cardiovascular disease (CVD) development. For that reason, the principal aim of primary and secondary cardiovascular prevention is to reach and sustain recommended LDL-C goals. Although there is a considerable body of evidence that shows that lowering LDL-C levels is directly associated with CVD risk reduction, recent data shows that the majority of patients across Europe cannot achieve their LDL-C targets. In attempting to address this matter, a new overarching concept of a lipid-lowering approach, comprising of even more intensive, much earlier and longer intervention to reduce LDL-C level, was recently proposed for high-risk patients. Another important concern is the residual risk for recurrent cardiovascular events despite optimal LDL-C reduction, suggesting that novel lipid biomarkers should also be considered as potential therapeutic targets. Among them, small dense LDL particles (sdLDL) seem to have the most significant potential for therapeutic modulation. This paper discusses the potential of traditional and emerging lipid-lowering approaches for cardiovascular prevention by targeting sdLDL particles.
PB  - MDPI
T2  - Pharmaceutics
T1  - Novel Pharmaceutical and Nutraceutical-Based Approaches for Cardiovascular Diseases Prevention Targeting Atherogenic Small Dense LDL
VL  - 14
IS  - 4
DO  - 10.3390/pharmaceutics14040825
ER  - 

@article{
author = "Vekić, Jelena and Zeljković, Aleksandra and Stefanović, Aleksandra and Bogavac-Stanojević, Nataša and Ilias, Ioannis and Silva-Nunes, José and Pantea Stoian, Anca and Janez, Andrej and Rizzo, Manfredi",
year = "2022",
abstract = "Compelling evidence supports the causative link between increased levels of low-density lipoprotein cholesterol (LDL-C) and atherosclerotic cardiovascular disease (CVD) development. For that reason, the principal aim of primary and secondary cardiovascular prevention is to reach and sustain recommended LDL-C goals. Although there is a considerable body of evidence that shows that lowering LDL-C levels is directly associated with CVD risk reduction, recent data shows that the majority of patients across Europe cannot achieve their LDL-C targets. In attempting to address this matter, a new overarching concept of a lipid-lowering approach, comprising of even more intensive, much earlier and longer intervention to reduce LDL-C level, was recently proposed for high-risk patients. Another important concern is the residual risk for recurrent cardiovascular events despite optimal LDL-C reduction, suggesting that novel lipid biomarkers should also be considered as potential therapeutic targets. Among them, small dense LDL particles (sdLDL) seem to have the most significant potential for therapeutic modulation. This paper discusses the potential of traditional and emerging lipid-lowering approaches for cardiovascular prevention by targeting sdLDL particles.",
publisher = "MDPI",
journal = "Pharmaceutics",
title = "Novel Pharmaceutical and Nutraceutical-Based Approaches for Cardiovascular Diseases Prevention Targeting Atherogenic Small Dense LDL",
volume = "14",
number = "4",
doi = "10.3390/pharmaceutics14040825"
}

Vekić, J., Zeljković, A., Stefanović, A., Bogavac-Stanojević, N., Ilias, I., Silva-Nunes, J., Pantea Stoian, A., Janez, A.,& Rizzo, M.. (2022). Novel Pharmaceutical and Nutraceutical-Based Approaches for Cardiovascular Diseases Prevention Targeting Atherogenic Small Dense LDL. in Pharmaceutics
MDPI., 14(4).
https://doi.org/10.3390/pharmaceutics14040825

Vekić J, Zeljković A, Stefanović A, Bogavac-Stanojević N, Ilias I, Silva-Nunes J, Pantea Stoian A, Janez A, Rizzo M. Novel Pharmaceutical and Nutraceutical-Based Approaches for Cardiovascular Diseases Prevention Targeting Atherogenic Small Dense LDL. in Pharmaceutics. 2022;14(4).
doi:10.3390/pharmaceutics14040825 .

Vekić, Jelena, Zeljković, Aleksandra, Stefanović, Aleksandra, Bogavac-Stanojević, Nataša, Ilias, Ioannis, Silva-Nunes, José, Pantea Stoian, Anca, Janez, Andrej, Rizzo, Manfredi, "Novel Pharmaceutical and Nutraceutical-Based Approaches for Cardiovascular Diseases Prevention Targeting Atherogenic Small Dense LDL" in Pharmaceutics, 14, no. 4 (2022),
https://doi.org/10.3390/pharmaceutics14040825 . .

TY  - JOUR
AU  - Vekić, Jelena
AU  - Zeljković, Aleksandra
AU  - Cicero, Arrigo F. G.
AU  - Janez, Andrej
AU  - Stoian, Anca Pantea
AU  - Sonmez, Alper
AU  - Rizzo, Manfredi
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4063
AB  - Atherosclerosis is responsible for large cardiovascular mortality in many countries globally. It has been shown over the last decades that the reduction of atherosclerotic progression is a critical factor for preventing future cardiovascular events. Low-density lipoproteins (LDL) have been successfully targeted, and their reduction is one of the key preventing measures in patients with atherosclerotic disease. LDL particles are pivotal for the formation and progression of atherosclerotic plaques; yet, they are quite heterogeneous, and smaller, denser LDL species are the most atherogenic. These particles have greater arterial entry and retention, higher susceptibility to oxidation, as well as reduced affinity for the LDL receptor. Increased proportion of small, dense LDL particles is an integral part of the atherogenic lipoprotein phenotype, the most common form of dyslipidemia associated with insulin resistance. Recent data suggest that both genetic and epigenetic factors might induce expression of this specific lipid pattern. In addition, a typical finding of increased small, dense LDL particles was confirmed in different categories of patients with elevated cardiovascular risk. Small, dense LDL is an independent risk factor for cardiovascular diseases, which emphasizes the clinical importance of both the quality and the quantity of LDL. An effective management of atherosclerotic disease should take into account the presence of small, dense LDL in order to prevent cardiovascular complications.
PB  - MDPI
T2  - Medicina
T1  - Atherosclerosis Development and Progression: The Role of
Atherogenic Small, Dense LDL
VL  - 58
IS  - 2
SP  - 299
DO  - 10.3390/medicina58020299
ER  - 

@article{
author = "Vekić, Jelena and Zeljković, Aleksandra and Cicero, Arrigo F. G. and Janez, Andrej and Stoian, Anca Pantea and Sonmez, Alper and Rizzo, Manfredi",
year = "2022",
abstract = "Atherosclerosis is responsible for large cardiovascular mortality in many countries globally. It has been shown over the last decades that the reduction of atherosclerotic progression is a critical factor for preventing future cardiovascular events. Low-density lipoproteins (LDL) have been successfully targeted, and their reduction is one of the key preventing measures in patients with atherosclerotic disease. LDL particles are pivotal for the formation and progression of atherosclerotic plaques; yet, they are quite heterogeneous, and smaller, denser LDL species are the most atherogenic. These particles have greater arterial entry and retention, higher susceptibility to oxidation, as well as reduced affinity for the LDL receptor. Increased proportion of small, dense LDL particles is an integral part of the atherogenic lipoprotein phenotype, the most common form of dyslipidemia associated with insulin resistance. Recent data suggest that both genetic and epigenetic factors might induce expression of this specific lipid pattern. In addition, a typical finding of increased small, dense LDL particles was confirmed in different categories of patients with elevated cardiovascular risk. Small, dense LDL is an independent risk factor for cardiovascular diseases, which emphasizes the clinical importance of both the quality and the quantity of LDL. An effective management of atherosclerotic disease should take into account the presence of small, dense LDL in order to prevent cardiovascular complications.",
publisher = "MDPI",
journal = "Medicina",
title = "Atherosclerosis Development and Progression: The Role of
Atherogenic Small, Dense LDL",
volume = "58",
number = "2",
pages = "299",
doi = "10.3390/medicina58020299"
}

Vekić, J., Zeljković, A., Cicero, A. F. G., Janez, A., Stoian, A. P., Sonmez, A.,& Rizzo, M.. (2022). Atherosclerosis Development and Progression: The Role of
Atherogenic Small, Dense LDL. in Medicina
MDPI., 58(2), 299.
https://doi.org/10.3390/medicina58020299

Vekić J, Zeljković A, Cicero AFG, Janez A, Stoian AP, Sonmez A, Rizzo M. Atherosclerosis Development and Progression: The Role of
Atherogenic Small, Dense LDL. in Medicina. 2022;58(2):299.
doi:10.3390/medicina58020299 .

Vekić, Jelena, Zeljković, Aleksandra, Cicero, Arrigo F. G., Janez, Andrej, Stoian, Anca Pantea, Sonmez, Alper, Rizzo, Manfredi, "Atherosclerosis Development and Progression: The Role of
Atherogenic Small, Dense LDL" in Medicina, 58, no. 2 (2022):299,
https://doi.org/10.3390/medicina58020299 . .

TY  - JOUR
AU  - Vekić, Jelena
AU  - Zeljković, Aleksandra
AU  - Rasadi, Khalid
AU  - Cesur, Mustafa
AU  - Silva-Nunes, José
AU  - Pantea Stoian, Anca
AU  - Rizzo, Manfredi
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4054
AB  - The presence of residual cardiovascular disease (CVD) risk is a current dilemma in clinical practice; indeed, despite optimal management and treatment, a considerable proportion of patients still undergo major CV events. Novel lipoprotein biomarkers are suggested as possible targets for improving the outcomes of patients at higher risk for CVD, and their impact on major CV events and mortality have previously been investigated. Innovative antidiabetic therapies have recently shown a significant reduction in atherogenic lipoproteins, beyond their effects on glucose parameters; it has also been suggested that such anti-atherogenic effect may represent a valuable mechanistic explanation for the cardiovascular benefit of, at least, some of the novel antidiabetic agents, such as glucagon-like peptide-1 receptor agonists. This emphasizes the need for further research in the field in order to clearly assess the effects of innovative treatments on different novel biomarkers, including atherogenic lipoproteins, such as small dense low-density lipoprotein (LDL), lipoprotein(a) (Lp(a)) and dysfunctional high-density lipoprotein (HDL). The current article discusses the clinical importance of novel lipid biomarkers for better management of patients in order to overcome residual cardiovascular risk.
PB  - MDPI
T2  - Metabolites
T1  - A New Look at Novel Cardiovascular Risk Biomarkers: The Role of Atherogenic Lipoproteins and Innovative Antidiabetic Therapies
VL  - 12
IS  - 2
DO  - 10.3390/metabo12020108
ER  - 

@article{
author = "Vekić, Jelena and Zeljković, Aleksandra and Rasadi, Khalid and Cesur, Mustafa and Silva-Nunes, José and Pantea Stoian, Anca and Rizzo, Manfredi",
year = "2022",
abstract = "The presence of residual cardiovascular disease (CVD) risk is a current dilemma in clinical practice; indeed, despite optimal management and treatment, a considerable proportion of patients still undergo major CV events. Novel lipoprotein biomarkers are suggested as possible targets for improving the outcomes of patients at higher risk for CVD, and their impact on major CV events and mortality have previously been investigated. Innovative antidiabetic therapies have recently shown a significant reduction in atherogenic lipoproteins, beyond their effects on glucose parameters; it has also been suggested that such anti-atherogenic effect may represent a valuable mechanistic explanation for the cardiovascular benefit of, at least, some of the novel antidiabetic agents, such as glucagon-like peptide-1 receptor agonists. This emphasizes the need for further research in the field in order to clearly assess the effects of innovative treatments on different novel biomarkers, including atherogenic lipoproteins, such as small dense low-density lipoprotein (LDL), lipoprotein(a) (Lp(a)) and dysfunctional high-density lipoprotein (HDL). The current article discusses the clinical importance of novel lipid biomarkers for better management of patients in order to overcome residual cardiovascular risk.",
publisher = "MDPI",
journal = "Metabolites",
title = "A New Look at Novel Cardiovascular Risk Biomarkers: The Role of Atherogenic Lipoproteins and Innovative Antidiabetic Therapies",
volume = "12",
number = "2",
doi = "10.3390/metabo12020108"
}

Vekić, J., Zeljković, A., Rasadi, K., Cesur, M., Silva-Nunes, J., Pantea Stoian, A.,& Rizzo, M.. (2022). A New Look at Novel Cardiovascular Risk Biomarkers: The Role of Atherogenic Lipoproteins and Innovative Antidiabetic Therapies. in Metabolites
MDPI., 12(2).
https://doi.org/10.3390/metabo12020108

Vekić J, Zeljković A, Rasadi K, Cesur M, Silva-Nunes J, Pantea Stoian A, Rizzo M. A New Look at Novel Cardiovascular Risk Biomarkers: The Role of Atherogenic Lipoproteins and Innovative Antidiabetic Therapies. in Metabolites. 2022;12(2).
doi:10.3390/metabo12020108 .

Vekić, Jelena, Zeljković, Aleksandra, Rasadi, Khalid, Cesur, Mustafa, Silva-Nunes, José, Pantea Stoian, Anca, Rizzo, Manfredi, "A New Look at Novel Cardiovascular Risk Biomarkers: The Role of Atherogenic Lipoproteins and Innovative Antidiabetic Therapies" in Metabolites, 12, no. 2 (2022),
https://doi.org/10.3390/metabo12020108 . .

TY  - JOUR
AU  - Vekić, Jelena
AU  - Silva-Nunes, José
AU  - Rizzo, Manfredi
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4264
PB  - MDPI
T2  - Metabolites
T1  - Glucose Metabolism Disorders: Challenges and Opportunities for Diagnosis and Treatment
VL  - 12
IS  - 8
DO  - 10.3390/metabo12080712
ER  - 

@article{
author = "Vekić, Jelena and Silva-Nunes, José and Rizzo, Manfredi",
year = "2022",
publisher = "MDPI",
journal = "Metabolites",
title = "Glucose Metabolism Disorders: Challenges and Opportunities for Diagnosis and Treatment",
volume = "12",
number = "8",
doi = "10.3390/metabo12080712"
}

Vekić, J., Silva-Nunes, J.,& Rizzo, M.. (2022). Glucose Metabolism Disorders: Challenges and Opportunities for Diagnosis and Treatment. in Metabolites
MDPI., 12(8).
https://doi.org/10.3390/metabo12080712

Vekić J, Silva-Nunes J, Rizzo M. Glucose Metabolism Disorders: Challenges and Opportunities for Diagnosis and Treatment. in Metabolites. 2022;12(8).
doi:10.3390/metabo12080712 .

Vekić, Jelena, Silva-Nunes, José, Rizzo, Manfredi, "Glucose Metabolism Disorders: Challenges and Opportunities for Diagnosis and Treatment" in Metabolites, 12, no. 8 (2022),
https://doi.org/10.3390/metabo12080712 . .

TY  - JOUR
AU  - Vekić, Jelena
AU  - Zeljković, Aleksandra
AU  - Stefanović, Aleksandra
AU  - Giglio, Rosaria Vincenza
AU  - Ciaccio, Marcello
AU  - Rizzo, Manfredi
PY  - 2021
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3992
AB  - Epidemiological data have demonstrated a significant association between the presence of type 2 diabetes mellitus (T2DM) and the development of colorectal cancer (CRC). Chronic hyperglycemia, insulin resistance, oxidative stress, and inflammation, the processes inherent to T2DM, also play active roles in the onset and progression of CRC. Recently, small dense low-density lipoprotein (LDL) particles, a typical characteristic of diabetic dyslipidemia, emerged as another possible underlying link between T2DM and CRC. Growing evidence suggests that antidiabetic medications may have beneficial effects in CRC prevention. According to findings from a limited number of preclinical and clinical studies, glucagon-like peptide-1 receptor agonists (GLP-1RAs) could be a promising strategy in reducing the incidence of CRC in patients with diabetes. However, available findings are inconclusive, and further studies are required. In this review, novel evidence on molecular mechanisms linking T2DM with CRC development, progression, and survival will be discussed. In addition, the potential role of GLP-1RAs therapies in CRC prevention will also be evaluated.
PB  - MDPI
T2  - International Journal of Molecular Sciences
T1  - Diabetes and colorectal cancer risk: A new look at molecular mechanisms and potential role of novel antidiabetic agents
VL  - 22
IS  - 22
DO  - 10.3390/ijms222212409
ER  - 

@article{
author = "Vekić, Jelena and Zeljković, Aleksandra and Stefanović, Aleksandra and Giglio, Rosaria Vincenza and Ciaccio, Marcello and Rizzo, Manfredi",
year = "2021",
abstract = "Epidemiological data have demonstrated a significant association between the presence of type 2 diabetes mellitus (T2DM) and the development of colorectal cancer (CRC). Chronic hyperglycemia, insulin resistance, oxidative stress, and inflammation, the processes inherent to T2DM, also play active roles in the onset and progression of CRC. Recently, small dense low-density lipoprotein (LDL) particles, a typical characteristic of diabetic dyslipidemia, emerged as another possible underlying link between T2DM and CRC. Growing evidence suggests that antidiabetic medications may have beneficial effects in CRC prevention. According to findings from a limited number of preclinical and clinical studies, glucagon-like peptide-1 receptor agonists (GLP-1RAs) could be a promising strategy in reducing the incidence of CRC in patients with diabetes. However, available findings are inconclusive, and further studies are required. In this review, novel evidence on molecular mechanisms linking T2DM with CRC development, progression, and survival will be discussed. In addition, the potential role of GLP-1RAs therapies in CRC prevention will also be evaluated.",
publisher = "MDPI",
journal = "International Journal of Molecular Sciences",
title = "Diabetes and colorectal cancer risk: A new look at molecular mechanisms and potential role of novel antidiabetic agents",
volume = "22",
number = "22",
doi = "10.3390/ijms222212409"
}

Vekić, J., Zeljković, A., Stefanović, A., Giglio, R. V., Ciaccio, M.,& Rizzo, M.. (2021). Diabetes and colorectal cancer risk: A new look at molecular mechanisms and potential role of novel antidiabetic agents. in International Journal of Molecular Sciences
MDPI., 22(22).
https://doi.org/10.3390/ijms222212409

Vekić J, Zeljković A, Stefanović A, Giglio RV, Ciaccio M, Rizzo M. Diabetes and colorectal cancer risk: A new look at molecular mechanisms and potential role of novel antidiabetic agents. in International Journal of Molecular Sciences. 2021;22(22).
doi:10.3390/ijms222212409 .

Vekić, Jelena, Zeljković, Aleksandra, Stefanović, Aleksandra, Giglio, Rosaria Vincenza, Ciaccio, Marcello, Rizzo, Manfredi, "Diabetes and colorectal cancer risk: A new look at molecular mechanisms and potential role of novel antidiabetic agents" in International Journal of Molecular Sciences, 22, no. 22 (2021),
https://doi.org/10.3390/ijms222212409 . .

TY  - JOUR
AU  - Vekić, Jelena
AU  - Joppa, Pavol
AU  - Habalova, Viera
AU  - Tisko, Radovan
AU  - Zeljković, Aleksandra
AU  - Pobeha, Pavol
AU  - Gojković, Tamara
AU  - Spasojević-Kalimanovska, Vesna
AU  - Strbova, Zuzana
AU  - Kuklisova, Zuzana
AU  - Slaba, Eva
AU  - Rizzo, Manfredi
AU  - Tkacova, Ruzena
PY  - 2016
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2765
AB  - Obstructive sleep apnea (OSA) is associated with dyslipidemia and increased cardiovascular risk. We assessed the effects of apolipoprotein E (APOE) genotype on low-density lipoprotein (LDL) and high-density lipoprotein (HDL) particle size and lipid subclasses (separated by gradient gel electrophoresis) in patients with OSA. Stable patients (n = 181) prospectively recruited underwent full polysomnography. Both LDL particle size and LDL I proportion were reduced from 33 homozygotes to 2 carriers and to 4 carriers (analysis of variance: P = .024; P = .040, respectively); carriers of the 4 allele of the APOE genotype had significantly lower LDL particle size and LDL I proportion compared to 33 homozygotes (P  lt  .05 for both comparisons). Insulin resistance increased from patients with no OSA to those with mild-moderate and to those with severe OSA (P  lt  .001). In multivariate analysis, LDL size was independently predicted by APOE genotype, male gender, and the presence of metabolic syndrome (MetS; P = .001, P = .020, P = .027, respectively). The HDL particle size was not affected by APOE genotype. Our data demonstrate that both the 4 APOE genotype and MetS are independently related to smaller LDL size in patients with OSA.
PB  - Sage Publications Inc, Thousand Oaks
T2  - Angiology
T1  - Relationship Between the Apolipoprotein E Genotype and LDL Particle Size in Patients With Obstructive Sleep Apnea
VL  - 67
IS  - 10
SP  - 937
EP  - 944
DO  - 10.1177/0003319716636512
ER  - 

@article{
author = "Vekić, Jelena and Joppa, Pavol and Habalova, Viera and Tisko, Radovan and Zeljković, Aleksandra and Pobeha, Pavol and Gojković, Tamara and Spasojević-Kalimanovska, Vesna and Strbova, Zuzana and Kuklisova, Zuzana and Slaba, Eva and Rizzo, Manfredi and Tkacova, Ruzena",
year = "2016",
abstract = "Obstructive sleep apnea (OSA) is associated with dyslipidemia and increased cardiovascular risk. We assessed the effects of apolipoprotein E (APOE) genotype on low-density lipoprotein (LDL) and high-density lipoprotein (HDL) particle size and lipid subclasses (separated by gradient gel electrophoresis) in patients with OSA. Stable patients (n = 181) prospectively recruited underwent full polysomnography. Both LDL particle size and LDL I proportion were reduced from 33 homozygotes to 2 carriers and to 4 carriers (analysis of variance: P = .024; P = .040, respectively); carriers of the 4 allele of the APOE genotype had significantly lower LDL particle size and LDL I proportion compared to 33 homozygotes (P  lt  .05 for both comparisons). Insulin resistance increased from patients with no OSA to those with mild-moderate and to those with severe OSA (P  lt  .001). In multivariate analysis, LDL size was independently predicted by APOE genotype, male gender, and the presence of metabolic syndrome (MetS; P = .001, P = .020, P = .027, respectively). The HDL particle size was not affected by APOE genotype. Our data demonstrate that both the 4 APOE genotype and MetS are independently related to smaller LDL size in patients with OSA.",
publisher = "Sage Publications Inc, Thousand Oaks",
journal = "Angiology",
title = "Relationship Between the Apolipoprotein E Genotype and LDL Particle Size in Patients With Obstructive Sleep Apnea",
volume = "67",
number = "10",
pages = "937-944",
doi = "10.1177/0003319716636512"
}

Vekić, J., Joppa, P., Habalova, V., Tisko, R., Zeljković, A., Pobeha, P., Gojković, T., Spasojević-Kalimanovska, V., Strbova, Z., Kuklisova, Z., Slaba, E., Rizzo, M.,& Tkacova, R.. (2016). Relationship Between the Apolipoprotein E Genotype and LDL Particle Size in Patients With Obstructive Sleep Apnea. in Angiology
Sage Publications Inc, Thousand Oaks., 67(10), 937-944.
https://doi.org/10.1177/0003319716636512

Vekić J, Joppa P, Habalova V, Tisko R, Zeljković A, Pobeha P, Gojković T, Spasojević-Kalimanovska V, Strbova Z, Kuklisova Z, Slaba E, Rizzo M, Tkacova R. Relationship Between the Apolipoprotein E Genotype and LDL Particle Size in Patients With Obstructive Sleep Apnea. in Angiology. 2016;67(10):937-944.
doi:10.1177/0003319716636512 .

Vekić, Jelena, Joppa, Pavol, Habalova, Viera, Tisko, Radovan, Zeljković, Aleksandra, Pobeha, Pavol, Gojković, Tamara, Spasojević-Kalimanovska, Vesna, Strbova, Zuzana, Kuklisova, Zuzana, Slaba, Eva, Rizzo, Manfredi, Tkacova, Ruzena, "Relationship Between the Apolipoprotein E Genotype and LDL Particle Size in Patients With Obstructive Sleep Apnea" in Angiology, 67, no. 10 (2016):937-944,
https://doi.org/10.1177/0003319716636512 . .

TY  - CONF
AU  - Tisko, Radovan
AU  - Jelić-Ivanović, Zorana
AU  - Habalova, Viera
AU  - Sopkova, Zuzana
AU  - Slaba, Eva
AU  - Vekić, Jelena
AU  - Dorkova, Zuzana
AU  - Zeljković, Aleksandra
AU  - Joppa, Pavol
AU  - Rizzo, Manfredi
AU  - Tkacova, Ruzena
PY  - 2013
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1886
PB  - European Respiratory Soc Journals Ltd, Sheffield
C3  - European Respiratory Journal
T1  - Predictors of lipoprotein particle size and subclasses in patients with OSA
VL  - 42
UR  - https://hdl.handle.net/21.15107/rcub_farfar_1886
ER  - 

@conference{
author = "Tisko, Radovan and Jelić-Ivanović, Zorana and Habalova, Viera and Sopkova, Zuzana and Slaba, Eva and Vekić, Jelena and Dorkova, Zuzana and Zeljković, Aleksandra and Joppa, Pavol and Rizzo, Manfredi and Tkacova, Ruzena",
year = "2013",
publisher = "European Respiratory Soc Journals Ltd, Sheffield",
journal = "European Respiratory Journal",
title = "Predictors of lipoprotein particle size and subclasses in patients with OSA",
volume = "42",
url = "https://hdl.handle.net/21.15107/rcub_farfar_1886"
}

Tisko, R., Jelić-Ivanović, Z., Habalova, V., Sopkova, Z., Slaba, E., Vekić, J., Dorkova, Z., Zeljković, A., Joppa, P., Rizzo, M.,& Tkacova, R.. (2013). Predictors of lipoprotein particle size and subclasses in patients with OSA. in European Respiratory Journal
European Respiratory Soc Journals Ltd, Sheffield., 42.
https://hdl.handle.net/21.15107/rcub_farfar_1886

Tisko R, Jelić-Ivanović Z, Habalova V, Sopkova Z, Slaba E, Vekić J, Dorkova Z, Zeljković A, Joppa P, Rizzo M, Tkacova R. Predictors of lipoprotein particle size and subclasses in patients with OSA. in European Respiratory Journal. 2013;42.
https://hdl.handle.net/21.15107/rcub_farfar_1886 .

Tisko, Radovan, Jelić-Ivanović, Zorana, Habalova, Viera, Sopkova, Zuzana, Slaba, Eva, Vekić, Jelena, Dorkova, Zuzana, Zeljković, Aleksandra, Joppa, Pavol, Rizzo, Manfredi, Tkacova, Ruzena, "Predictors of lipoprotein particle size and subclasses in patients with OSA" in European Respiratory Journal, 42 (2013),
https://hdl.handle.net/21.15107/rcub_farfar_1886 .

TY  - JOUR
AU  - Rizzo, Manfredi
AU  - Vekić, Jelena
AU  - Koulouris, Spyridon
AU  - Zeljković, Aleksandra
AU  - Jelić-Ivanović, Zorana
AU  - Spasojević-Kalimanovska, Vesna
AU  - Rini, Giovam Battista
AU  - Sakellariou, Dimitrios
AU  - Pastromas, Socrates
AU  - Mikhailidis, Dimitri P.
AU  - Manolis, Antonis S.
PY  - 2010
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1398
AB  - Rosiglitazone may increase cardiovascular risk in patients with type 2 diabetes. Yet, its effects on atherogenic dyslipidemia are still not fully elucidated. In a prospective open-label study rosiglitazone (4 mg/day for 12 weeks) was added to a maximum of 2 oral antidiabetic drugs in 18 diabetic patients. We evaluated the effects on plasma lipids before and after an oral fat load. The size and subclasses of low-density lipoprotein (LDL) and high-density lipoprotein (HDL) were also determined (by gradient gel electrophoresis). Rosiglitazone improved glycosylated hemoglobin ([HbAlc] P = .0023), without significant effects on fasting and postprandial plasma lipids. Fasting LDL size increased (+1.4%, P = .034), with less small, dense LDL-IIIA (-25.1%, P = .018). Postprandially, larger HDL-2b reduced (-8.7%, P = .006) and smaller HDL-3b increased (+12.2%, P = .05), without any effects on HDL size. Rosiglitazone led to antiatherogenic changes in LDL size and subclasses, with proatherogenic changes in HDL subclasses, despite no effects on plasma lipids. Their clinical relevance remains to be established.
PB  - Sage Publications Inc, Thousand Oaks
T2  - Angiology
T1  - Effects of Rosiglitazone on Fasting and Postprandial Low- and High-Density Lipoproteins Size and Subclasses in Type 2 Diabetes
VL  - 61
IS  - 6
SP  - 584
EP  - 590
DO  - 10.1177/0003319710366431
ER  - 

@article{
author = "Rizzo, Manfredi and Vekić, Jelena and Koulouris, Spyridon and Zeljković, Aleksandra and Jelić-Ivanović, Zorana and Spasojević-Kalimanovska, Vesna and Rini, Giovam Battista and Sakellariou, Dimitrios and Pastromas, Socrates and Mikhailidis, Dimitri P. and Manolis, Antonis S.",
year = "2010",
abstract = "Rosiglitazone may increase cardiovascular risk in patients with type 2 diabetes. Yet, its effects on atherogenic dyslipidemia are still not fully elucidated. In a prospective open-label study rosiglitazone (4 mg/day for 12 weeks) was added to a maximum of 2 oral antidiabetic drugs in 18 diabetic patients. We evaluated the effects on plasma lipids before and after an oral fat load. The size and subclasses of low-density lipoprotein (LDL) and high-density lipoprotein (HDL) were also determined (by gradient gel electrophoresis). Rosiglitazone improved glycosylated hemoglobin ([HbAlc] P = .0023), without significant effects on fasting and postprandial plasma lipids. Fasting LDL size increased (+1.4%, P = .034), with less small, dense LDL-IIIA (-25.1%, P = .018). Postprandially, larger HDL-2b reduced (-8.7%, P = .006) and smaller HDL-3b increased (+12.2%, P = .05), without any effects on HDL size. Rosiglitazone led to antiatherogenic changes in LDL size and subclasses, with proatherogenic changes in HDL subclasses, despite no effects on plasma lipids. Their clinical relevance remains to be established.",
publisher = "Sage Publications Inc, Thousand Oaks",
journal = "Angiology",
title = "Effects of Rosiglitazone on Fasting and Postprandial Low- and High-Density Lipoproteins Size and Subclasses in Type 2 Diabetes",
volume = "61",
number = "6",
pages = "584-590",
doi = "10.1177/0003319710366431"
}

Rizzo, M., Vekić, J., Koulouris, S., Zeljković, A., Jelić-Ivanović, Z., Spasojević-Kalimanovska, V., Rini, G. B., Sakellariou, D., Pastromas, S., Mikhailidis, D. P.,& Manolis, A. S.. (2010). Effects of Rosiglitazone on Fasting and Postprandial Low- and High-Density Lipoproteins Size and Subclasses in Type 2 Diabetes. in Angiology
Sage Publications Inc, Thousand Oaks., 61(6), 584-590.
https://doi.org/10.1177/0003319710366431

Rizzo M, Vekić J, Koulouris S, Zeljković A, Jelić-Ivanović Z, Spasojević-Kalimanovska V, Rini GB, Sakellariou D, Pastromas S, Mikhailidis DP, Manolis AS. Effects of Rosiglitazone on Fasting and Postprandial Low- and High-Density Lipoproteins Size and Subclasses in Type 2 Diabetes. in Angiology. 2010;61(6):584-590.
doi:10.1177/0003319710366431 .

Rizzo, Manfredi, Vekić, Jelena, Koulouris, Spyridon, Zeljković, Aleksandra, Jelić-Ivanović, Zorana, Spasojević-Kalimanovska, Vesna, Rini, Giovam Battista, Sakellariou, Dimitrios, Pastromas, Socrates, Mikhailidis, Dimitri P., Manolis, Antonis S., "Effects of Rosiglitazone on Fasting and Postprandial Low- and High-Density Lipoproteins Size and Subclasses in Type 2 Diabetes" in Angiology, 61, no. 6 (2010):584-590,
https://doi.org/10.1177/0003319710366431 . .

TY  - JOUR
AU  - Rizzo, Manfredi
AU  - Kotur-Stevuljević, Jelena
AU  - Berneis, Kaspar
AU  - Spinas, Giatgen
AU  - Rini, Giovam Battista
AU  - Jelić-Ivanović, Zorana
AU  - Spasojević-Kalimanovska, Vesna
AU  - Vekić, Jelena
PY  - 2009
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1228
AB  - Although results from in vitro studies and clinical trials demonstrate strong associations between oxidative stress and cardiovascular risk, to date still no convincing data are available to suggest that treatment with antioxidants might reduce vascular events. Oxidative modifications of low-density lipoproteins (LDL) represent an early stage of atherosclerosis, and small, dense LDL are more susceptible to oxidation than larger, more buoyant particles. Oxidized LDL are independent predictors of subclinical and clinical atherosclerosis. Recent studies suggested that novel therapeutic strategies may take into account the removal of such particles from circulation. Future research is required to explore the potential synergistic impact of markers of oxidative stress and atherogenic dyslipidemia, particularly small dense LDL, on cardiovascular risk. (Translational Research 2009; 153:217-223)
PB  - Elsevier Science Inc, New York
T2  - Transplant International
T1  - Atherogenic dyslipidemia and oxidative stress: a new look
VL  - 153
IS  - 5
SP  - 217
EP  - 223
DO  - 10.1016/j.trsl.2009.01.008
ER  - 

@article{
author = "Rizzo, Manfredi and Kotur-Stevuljević, Jelena and Berneis, Kaspar and Spinas, Giatgen and Rini, Giovam Battista and Jelić-Ivanović, Zorana and Spasojević-Kalimanovska, Vesna and Vekić, Jelena",
year = "2009",
abstract = "Although results from in vitro studies and clinical trials demonstrate strong associations between oxidative stress and cardiovascular risk, to date still no convincing data are available to suggest that treatment with antioxidants might reduce vascular events. Oxidative modifications of low-density lipoproteins (LDL) represent an early stage of atherosclerosis, and small, dense LDL are more susceptible to oxidation than larger, more buoyant particles. Oxidized LDL are independent predictors of subclinical and clinical atherosclerosis. Recent studies suggested that novel therapeutic strategies may take into account the removal of such particles from circulation. Future research is required to explore the potential synergistic impact of markers of oxidative stress and atherogenic dyslipidemia, particularly small dense LDL, on cardiovascular risk. (Translational Research 2009; 153:217-223)",
publisher = "Elsevier Science Inc, New York",
journal = "Transplant International",
title = "Atherogenic dyslipidemia and oxidative stress: a new look",
volume = "153",
number = "5",
pages = "217-223",
doi = "10.1016/j.trsl.2009.01.008"
}

Rizzo, M., Kotur-Stevuljević, J., Berneis, K., Spinas, G., Rini, G. B., Jelić-Ivanović, Z., Spasojević-Kalimanovska, V.,& Vekić, J.. (2009). Atherogenic dyslipidemia and oxidative stress: a new look. in Transplant International
Elsevier Science Inc, New York., 153(5), 217-223.
https://doi.org/10.1016/j.trsl.2009.01.008

Rizzo M, Kotur-Stevuljević J, Berneis K, Spinas G, Rini GB, Jelić-Ivanović Z, Spasojević-Kalimanovska V, Vekić J. Atherogenic dyslipidemia and oxidative stress: a new look. in Transplant International. 2009;153(5):217-223.
doi:10.1016/j.trsl.2009.01.008 .

Rizzo, Manfredi, Kotur-Stevuljević, Jelena, Berneis, Kaspar, Spinas, Giatgen, Rini, Giovam Battista, Jelić-Ivanović, Zorana, Spasojević-Kalimanovska, Vesna, Vekić, Jelena, "Atherogenic dyslipidemia and oxidative stress: a new look" in Transplant International, 153, no. 5 (2009):217-223,
https://doi.org/10.1016/j.trsl.2009.01.008 . .

TY  - JOUR
AU  - Rizzo, Manfredi
AU  - Berneis, Kaspar
AU  - Zeljković, Aleksandra
AU  - Vekić, Jelena
PY  - 2009
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1190
AB  - Low-density lipoprotein (LDL) and high-density lipoprotein (HDL) plasma populations are composed of heterogeneous subfractions that are different in size, density and protein/lipid content. There is increasing evidence that small, dense LDL particles are strongly associated with higher cardiovascular disease risk. Similarly, several studies have investigated whether smaller HDL particles are more protective than their larger counterparts and more recent findings suggest that small, dense HDL has significantly higher atheroprotective activity than larger L HDL. Yet, certain impairments of the protein/lipid content in small, dense HDL may decrease its antiatherogenic capacity or even induce pro-atherogenic properties. Therefore, it seems that the small, dense phenomenon applies to both LDL and HDL particles. Measurement of LDL and HDL cholesterol concentrations has proven clinical utility, while the usefulness of LDL and HDL subclasses determination in clinical practice offers grounds for further exploration. However, LDL and HDL particles characterisation requires either special equipment or a lengthy analytical time and is, therefore, still unsuitable for general clinical use. It remains to be established whether lipoprotein subclasses should be analyzed in routine practice, although their assessment in high-risk subjects could be recommended. (Clin. Lab. 2009;55:421-429)
PB  - Clin Lab Publ, Heidelberg
T2  - Clinical Laboratory
T1  - Should we routinely measure low-density and high-density lipoprotein subclasses?
VL  - 55
IS  - 11-12
SP  - 421
EP  - 429
UR  - https://hdl.handle.net/21.15107/rcub_farfar_1190
ER  - 

@article{
author = "Rizzo, Manfredi and Berneis, Kaspar and Zeljković, Aleksandra and Vekić, Jelena",
year = "2009",
abstract = "Low-density lipoprotein (LDL) and high-density lipoprotein (HDL) plasma populations are composed of heterogeneous subfractions that are different in size, density and protein/lipid content. There is increasing evidence that small, dense LDL particles are strongly associated with higher cardiovascular disease risk. Similarly, several studies have investigated whether smaller HDL particles are more protective than their larger counterparts and more recent findings suggest that small, dense HDL has significantly higher atheroprotective activity than larger L HDL. Yet, certain impairments of the protein/lipid content in small, dense HDL may decrease its antiatherogenic capacity or even induce pro-atherogenic properties. Therefore, it seems that the small, dense phenomenon applies to both LDL and HDL particles. Measurement of LDL and HDL cholesterol concentrations has proven clinical utility, while the usefulness of LDL and HDL subclasses determination in clinical practice offers grounds for further exploration. However, LDL and HDL particles characterisation requires either special equipment or a lengthy analytical time and is, therefore, still unsuitable for general clinical use. It remains to be established whether lipoprotein subclasses should be analyzed in routine practice, although their assessment in high-risk subjects could be recommended. (Clin. Lab. 2009;55:421-429)",
publisher = "Clin Lab Publ, Heidelberg",
journal = "Clinical Laboratory",
title = "Should we routinely measure low-density and high-density lipoprotein subclasses?",
volume = "55",
number = "11-12",
pages = "421-429",
url = "https://hdl.handle.net/21.15107/rcub_farfar_1190"
}

Rizzo, M., Berneis, K., Zeljković, A.,& Vekić, J.. (2009). Should we routinely measure low-density and high-density lipoprotein subclasses?. in Clinical Laboratory
Clin Lab Publ, Heidelberg., 55(11-12), 421-429.
https://hdl.handle.net/21.15107/rcub_farfar_1190

Rizzo M, Berneis K, Zeljković A, Vekić J. Should we routinely measure low-density and high-density lipoprotein subclasses?. in Clinical Laboratory. 2009;55(11-12):421-429.
https://hdl.handle.net/21.15107/rcub_farfar_1190 .

Rizzo, Manfredi, Berneis, Kaspar, Zeljković, Aleksandra, Vekić, Jelena, "Should we routinely measure low-density and high-density lipoprotein subclasses?" in Clinical Laboratory, 55, no. 11-12 (2009):421-429,
https://hdl.handle.net/21.15107/rcub_farfar_1190 .